TBXT and hereditary clear cell renal cell carcinoma: Licensing of newer agents, such as new oral kinase inhibitors and T-cell checkpoint inhibitor immunotherapy, will inevitably change the way some cancers, such as renal cell carcinoma, are currently treated.